RNF169 and pancreatic adenocarcinoma: To further verify the results above, we performed survival analysis with the TIMER (Supplementary Figure S2A) and UALCAN (Supplementary Figure S2B) databases and found that PAAD patients with lower RNF169 expression had better cumulative survival.